Cell Therapeutics Inc. (CTIC US) rose 8.9 percent to $1.10 after gaining 16 percent earlier, the biggest intraday rise since Dec. 6. The Food and Drug Administration said the company’s pixantrone, which is under review for adults with non- Hodgkin’s lymphoma who received two or more prior lines of therapy, will be discussed by an advisory committee on Feb. 9.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.